Toxicological Activities of Pteridium aquilinum Rhizomes and Fiddleheads in HPV16-Transgenic Mice
Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Bracken Samples
2.1.1. Sample Treatment and Storage
2.1.2. Sample Preparation
2.1.3. Chemical Composition
2.2. Mice
2.3. Experimental Procedures
2.3.1. Sample Collection and Hematology and Biochemical Analyses
2.3.2. Histological Analysis
2.3.3. Comet Assay
2.3.4. Hepatic and Kidney Oxidative Stress
2.4. Statistical Analysis
- ▪
- Humane endpoints = (sum score per animal)/(number of animals per cage).
- ▪
- Weight gain = ((final weight − initial weight)/(initial weight)) × 100 (%).
- ▪
- Average daily consumption (drink/food) per animal per day = ((initial weight) − (final weight))/(number of days between weightings) × (number of animals per cage) (g).
- ▪
- Relative weight of organs = (organ weight)/(body weight) (mg/g).
3. Results
3.1. Chemical Composition
3.2. General Findings
3.3. Hematology and Biochemical Analyses
3.4. Comet Assay
3.5. Histology
3.6. Hepatic and Renal Oxidative Stress
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Conflicts of Interest
References
- Vetter, J. A biological hazard of our age: Bracken fern [Pteridium aquilinum (L.) Kuhn]—A review. Acta Vet. Hung. 2009, 57, 183–196. [Google Scholar] [CrossRef] [PubMed]
- Tourchi-Roudsari, M. Multiple effects of bracken fern under in vivo and in vitro conditions. Asian Pac. J. Cancer Prev. 2024, 15, 7505–7513. [Google Scholar] [CrossRef]
- Smith, B.L.; Seawright, A.A. Bracken fern (Pteridium spp.) carcinogenicity and human health—A brief review. Nat. Toxins 1995, 3, 1–5. [Google Scholar] [CrossRef] [PubMed]
- Yamada, K.; Ojika, M.; Kigoshi, H. Ptaquiloside, the major toxin of bracken, and related terpene glycosides: Chemistry, biology and ecology. Nat. Prod. Rep. 2007, 24, 798–813. [Google Scholar] [CrossRef] [PubMed]
- Hirono, I.; Shibuya, C.; Fushimi, K.; Haga, M. Studies on carcinogenic properties of bracken, Pteridium aquilinum. J. Natl. Cancer Inst. 1970, 45, 179–188. [Google Scholar] [CrossRef]
- Alonso-Amelot, M.E.; Castillo, U.; Smith, B.L.; Lauren, D.R. Bracken ptaquiloside in milk. Nature 1996, 382, 587. [Google Scholar] [CrossRef] [PubMed]
- Rasmussen, L.H.; Jensen, L.S.; Hansen, H.C.B. Distribution of the carcinogenic terpene ptaquiloside in bracken fronds, rhizomes (Pteridium aquilinum), and litter in Denmark. J. Chem. Ecol. 2003, 29, 771–778. [Google Scholar] [CrossRef] [PubMed]
- França, T.N.; Tokarnia, C.H.; Peixoto, P.V. Enfermidades determinadas pelo princípio radiomimético de Pteridium aquilinum (Polypodiaceae). Pesq. Vet. Bras. 2002, 22, 85–96. [Google Scholar] [CrossRef]
- Iwao, H.; Katsumasa, F.; Nagaki, M. Carcinogenicity test of shikimic acid in rats. Toxicol. Lett. 1977, 1, 9–10. [Google Scholar] [CrossRef]
- Pamukcu, A.M.; Yalçiner, S.; Hatcher, J.F.; Bryan, G.T. Quercetin, a rat intestinal and bladder carcinogen present in bracken fern (Pteridium aquilinum). Cancer Res. 1980, 40, 3468–3472. [Google Scholar] [PubMed]
- Zhou, S.; Dong, W.; Chen, X.; Zhang, X.; Wen, J.; Schneider, H. How many species of bracken (Pteridium) are there? Assessing the Chinese brackens using molecular evidence. Taxon 2014, 63, 509–521. [Google Scholar] [CrossRef]
- Sachetin Marçal, W. A intoxicação por samambaia em bovinos criados no Estado do Paraná. Semin. Ciênc. Agrár. 2003, 24, 197–208. [Google Scholar] [CrossRef]
- Durante Cruz, G.; Paula, F.R.L.; Bracarense, A. Toxicidade da samambaia (Pteridium aquilinum (L.) Kuhn) para a saúde animal e humana. Semin. Ciênc. Agrár. 2004, 25, 249–258. [Google Scholar] [CrossRef]
- Smith, B.L. Bracken fern (genus Pteridium) toxicity—A global problem. In Poisonous Plants and Related Toxins; Acamovic, T., Stewart, C.S., Pennycott, T.W., Eds.; CABI Publishing: London, UK, 2004; pp. 227–240. [Google Scholar]
- Gil da Costa, R.M.; Medeiros, R. Bovine papillomavirus: Opening new trends for comparative pathology. Arch. Virol. 2014, 159, 191–198. [Google Scholar] [CrossRef] [PubMed]
- Arbeit, J.M.; Münger, K.; Howley, P.M.; Hanahan, D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol. 1994, 68, 4358–4368. [Google Scholar] [CrossRef] [PubMed]
- Masset, A.; Maillard, C.; Sounni, N.E.; Jacobs, N.; Bruyére, F.; Delvenne, P.; Tacke, M.; Reinheckel, T.; Foidart, J.-M.; Coussens, L.M.; et al. Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor. Int. J. Cancer 2011, 128, 283–293. [Google Scholar] [CrossRef] [PubMed]
- Costa, R.M.G.; Neto, T.; Estêvão, D.; Moutinho, M.; Félix, A.; Medeiros, R.; Lopes, C.; Bastos, M.M.S.M.; Oliveira, P.A. Ptaquiloside from bracken (Pteridium spp.) promotes oral carcinogenesis initiated by HPV16 in transgenic mice. Food Funct. 2020, 11, 3298–3305. [Google Scholar] [CrossRef] [PubMed]
- Duan, X.-G. Study on acute toxicity of Pteridium aquilinum tea in mice. Chem. Beverage Ind. 2007, 10, 29–30. (In Chinese) [Google Scholar]
- Takahashi, A. Toward understanding the sex differences in the biological mechanism of social stress in mouse models. Front. Psychiatry 2021, 12, 644161. [Google Scholar] [CrossRef] [PubMed]
- Arbeit, J.M.; Olson, D.C.; Hanahan, D. Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice. Oncogene 1996, 13, 1847–1857. [Google Scholar] [PubMed]
- Paiva, I.; Gil da Costa, R.M.; Ribeiro, J.; Sousa, H.; Bastos, M.M.S.M.; Faustino-Rocha, A.; Lopes, C.; Oliveira, P.A.; Medeiros, R. MicroRNA-21 expression and susceptibility to HPV-induced carcinogenesis—Role of microenvironment in K14-HPV16 mice model. Life Sci. 2015, 128, 8–14. [Google Scholar] [CrossRef] [PubMed]
- Silva-Reis, R.; Faustino-Rocha, A.I.; Gonçalves, M.; Ribeiro, C.C.; Ferreira, T.; Ribeiro-Silva, C.; Gonçalves, L.; Antunes, L.; Venâncio, C.; Ferreira, R.; et al. Refinement of animal model of colorectal carcinogenesis through the definition of novel humane endpoints. Animals 2021, 11, 985. [Google Scholar] [CrossRef] [PubMed]
- Oliveira, M.; Nascimento-Gonçalves, E.; Silva, J.; Oliveira, P.A.; Ferreira, R.; Antunes, L.; Arantes-Rodrigues, R.; Faustino-Rocha, A.I. Implementation of humane endpoints in a urinary bladder carcinogenesis study in rats. In Vivo 2017, 31, 1073–1080. [Google Scholar] [CrossRef] [PubMed]
- Forbes, D.; Blom, H.J.M.; Kostomitsopoulos, N.; Moore, G.; Perretta, G. FELASA Euroguide: On the Accommodation and Care of Animals Used for Experimental and Other Scientific Purposes; FELASA: London, UK, 2007. [Google Scholar]
- Santos, C.; Neto, T.; Ferreirinha, P.; Sousa, H.; Ribeiro, J.; Bastos, M.M.S.M.; Faustino-Rocha, A.I.; Oliveira, P.A.; Medeiros, R.; Vilanova, M.; et al. Celecoxib promotes degranulation of CD8(+) T cells in HPV-induced lesions of K14-HPV16 transgenic mice. Life Sci. 2016, 157, 67–73. [Google Scholar] [CrossRef] [PubMed]
- Gil da Costa, R.M.; Aragão, S.; Moutinho, M.; Alvarado, A.; Casaca, D.F.; Silva, S.M.; Ribeiro, J.; Sousa, H.; Ferreira, R.; Nogueira-Ferreira, R.; et al. HPV16 induces a wasting syndrome in transgenic mice: Amelioration by dietary polyphenols via NF-κB inhibition. Life Sci. 2017, 169, 11–19. [Google Scholar] [CrossRef] [PubMed]
- Azqueta, A.; Collins, A.R. The comet assay: High throughput use of FPG. In Genotoxicity and DNA Repair: A Practical Approach; Sierra, L.M., Gaivão, I., Eds.; Springer: New York, NY, USA, 2014; pp. 199–217. [Google Scholar]
- New England Biolabs. Fpg. Available online: https://www.neb.com/en/products/m0240-fpg#Product%20Information (accessed on 13 January 2024).
- Collins, A.R. The comet assay for DNA damage and repair: Principles, applications, and limitations. Mol. Biotechnol. 2004, 26, 249–261. [Google Scholar] [CrossRef] [PubMed]
- Durak, I.; Yurtarslanli, Z.; Canbolat, O.; Akyol, O. A methodological approach to superoxide dismutase (SOD) activity assay based on inhibition of nitroblue tetrazolium (NBT) reduction. Clin. Chim. Acta 1993, 214, 103–104. [Google Scholar] [CrossRef] [PubMed]
- Gartaganis, S.P.; Patsoukis, N.E.; Nikolopoulos, D.K.; Georgiou, C.D. Evidence for oxidative stress in lens epithelial cells in pseudoexfoliation syndrome. Eye 2007, 21, 1406–1411. [Google Scholar] [CrossRef] [PubMed]
- Shivapriya, S.; Ilango, K.; Dubey, G.P. Evaluation of antioxidant and neuroprotective effect of Hippophae rhamnoides (L.) on oxidative stress induced cytotoxicity in human neural cell line IMR32. Saudi J. Biol. Sci. 2015, 22, 645–650. [Google Scholar] [CrossRef] [PubMed]
- Wallin, B.; Rosengren, B.; Shertzer, H.G.; Camejo, G. Lipoprotein oxidation and measurement of thiobarbituric acid reacting substances formation in a single microtiter plate: Its use for evaluation of antioxidants. Anal. Biochem. 1993, 208, 10–15. [Google Scholar] [CrossRef] [PubMed]
- Nakamura, W.; Hosoda, S.; Hayashi, K. Purification and properties of rat liver glutathione peroxidase. Biochim. Biophys. Acta 1974, 358, 251–261. [Google Scholar] [CrossRef]
- Forstrom, J.W.; Zakowski, J.J.; Tappel, A.L. Identification of the catalytic site of rat liver glutathione peroxidase as selenocysteine. Biochemistry 1978, 17, 2639–2644. [Google Scholar] [CrossRef] [PubMed]
- PubChem. Pteroside C. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/169728 (accessed on 1 June 2023).
- PubChem. Pteroside P. National Center for Biotechnology Information. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/148715 (accessed on 1 June 2023).
- PubChem. Pteroside M. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/102090488 (accessed on 1 October 2023).
- PubChem. Pteroside W. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/101593494 (accessed on 1 October 2023).
- PubChem. Pteroside X. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/92023872 (accessed on 1 October 2023).
- PubChem. Pteroside A. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/169727 (accessed on 1 October 2023).
- PubChem. Pteroside D. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/169738 (accessed on 1 October 2023).
- Allverdú-Queralt, A.; Jáuregui, O.; Di Lecce, G.; Andrés-Lacueva, C.; Lamuela-Raventós, R.M. Screening of the polyphenol content of tomato-based products through accurate-mass spectrometry (HPLC–ESI-QTOF). Food Chem. 2011, 129, 877–883. [Google Scholar] [CrossRef]
- Wada, H.; Kida, T.; Tanaka, N.; Murakami, T.; Saik, Y.; Chen, C.M. Chemical and chemotaxonomical studies of ferns: LXXXI. Characteristic lignans of blechnaceous ferns. Chem. Pharm. Bull. 1992, 40, 2099–2101. [Google Scholar] [CrossRef]
- Gyeltshen, T.; Smith, J.A.; Bissember, A.C. Natural products isolation studies of native Australian fern species. Aust. J. Chem. 2022, 75, 422–437. [Google Scholar] [CrossRef]
- Gouveia, S.; Castilho, P.C. Characterisation of phenolic acid derivatives and flavonoids from different morphological parts of Helichrysum obconicum by a RP-HPLC-DAD-(-)-ESI-MSn method. Food Chem. 2011, 129, 333–344. [Google Scholar] [CrossRef] [PubMed]
- Barros, L.; Dueñas, M.; Dias, M.I.; Sousa, M.J.; Santos-Buelga, C.; Ferreira, I.C.F.R. Phenolic profiles of in vivo and in vitro grown Coriandrum sativum L. Food Chem. 2012, 132, 841–848. [Google Scholar] [CrossRef]
- Llorent-Martínez, E.J.; Spínola, V.; Gouveia, S.; Castilho, P.C. HPLC-ESI-MSn characterization of phenolic compounds, terpenoid saponins, and other minor compounds in Bituminaria bituminosa. Ind. Crops Prod. 2015, 69, 80–90. [Google Scholar] [CrossRef]
- Spínola, V.; Llorent-Martínez, E.J.; Gouveia-Figueira, S.; Castilho, P.C. Ulex europaeus: From noxious weed to source of valuable isoflavones and flavanones. Ind. Crops Prod. 2016, 90, 9–27. [Google Scholar] [CrossRef]
- Skrbic, N.; Pedersen, A.K.; Christensen, S.C.B.; Hansen, H.C.B.; Rasmussen, L.H. A novel method for determination of the natural toxin ptaquiloside in ground and drinking water. Water 2020, 12, 2852. [Google Scholar] [CrossRef]
- Gil da Costa, R.M.; Povey, A.; Medeiros-Fonseca, B.; Ramwell, C.; O’Driscoll, C.; Williams, D.; Hansen, H.C.B.; Rasmussen, L.H.; Fletcher, M.T.; O’Connor, P.; et al. Sixty years of research on bracken fern (Pteridium spp.) toxins: Environmental exposure, health risks and recommendations for bracken fern control. Environ. Res. 2024, 257, 119274. [Google Scholar] [CrossRef] [PubMed]
- Imperato, F. Flavonol glycosides from Pteridium aquilinum. Phytochemistry 1995, 40, 1801–1802. [Google Scholar] [CrossRef]
- Medeiros-Fonseca, B.; Abreu-Silva, A.L.; Medeiros, R.; Oliveira, P.A.; Gil da Costa, R.M. Pteridium spp. and bovine papillomavirus: Partners in cancer. Front. Vet. Sci. 2021, 8, 758720. [Google Scholar] [CrossRef] [PubMed]
- Evans, I.A.; Mason, J. Carcinogenic activity of bracken. Nature 1965, 208, 913–914. [Google Scholar] [CrossRef] [PubMed]
- Alonso-Amelot, M.E. The chemistry and toxicology of bioactive compounds in bracken fern (Pteridium spp.), with special reference to chemical ecology and carcinogenesis. In Studies in Natural Products Chemistry; Atta-ur-Rahman, Ed.; Elsevier: Amsterdam, The Netherlands, 2002; pp. 685–739. [Google Scholar]
- Mestre, V.F.; Medeiros-Fonseca, B.; Estêvão, D.; Casaca, F.; Silva, S.; Félix, A.; Silva, F.; Colaço, B.; Seixas, F.; Bastos, M.M.S.M.; et al. HPV16 is sufficient to induce squamous cell carcinoma specifically in the tongue base in transgenic mice. J. Pathol. 2020, 251, 4–11. [Google Scholar] [CrossRef] [PubMed]
- Mohammad, R.H.; Nur-e-Alam, M.; Lahmann, M.; Parveen, I.; Tizzard, G.J.; Coles, S.J.; Fowler, M.; Drake, A.F.; Heyes, D.; Thoss, V.; et al. Isolation and characterisation of 13 pterosins and pterosides from bracken (Pteridium aquilinum (L.) Kuhn) rhizome. Phytochemistry 2016, 128, 82–94. [Google Scholar] [CrossRef] [PubMed]
- Peixoto da Silva, S.; Santos, J.M.O.; Mestre, V.F.; Medeiros-Fonseca, B.; Oliveira, P.A.; MSM Bastos, M.; Gil da Costa, R.M.; Medeiros, R. Human papillomavirus 16-transgenic mice as a model to study cancer-associated cachexia. Int. J. Mol. Sci. 2020, 21, 5020. [Google Scholar] [CrossRef] [PubMed]
- Santos, C.; Ferreirinha, P.; Sousa, H.; Ribeiro, J.; Bastos, M.M.S.M.; Neto, T.; Oliveira, P.A.; Medeiros, R.; Vilanova, M.; Gil da Costa, R.M.; et al. Ptaquiloside from bracken (Pteridium spp.) inhibits tumour-infiltrating CD8+ T cells in HPV-16 transgenic mice. Food Chem. Toxicol. 2016, 97, 277–285. [Google Scholar] [CrossRef] [PubMed]
- Araújo, R.; Santos, J.M.O.; Fernandes, M.; Dias, F.; Sousa, H.; Ribeiro, J.; Bastos, M.M.S.M.; Oliveira, P.A.; Carmo, D.; Casaca, F.; et al. Expression profile of microRNA-146a along HPV-induced multistep carcinogenesis: A study in HPV16 transgenic mice. J. Cancer Res. Clin. Oncol. 2018, 144, 241–248. [Google Scholar] [CrossRef] [PubMed]
- Medeiros-Fonseca, B.; Mestre, V.F.; Colaço, B.; Pires, M.J.; Martins, T.; Gil da Costa, R.M.; Neuparth, M.J.; Medeiros, R.; Moutinho, M.S.S.; Dias, M.I.; et al. Laurus nobilis (laurel) aqueous leaf extract’s toxicological and anti-tumor activities in HPV16-transgenic mice. Food Funct. 2018, 9, 4419–4428. [Google Scholar] [CrossRef] [PubMed]
- Santos, C.; Vilanova, M.; Medeiros, R.; Gil da Costa, R.M. HPV-transgenic mouse models: Tools for studying the cancer-associated immune response. Virus Res. 2017, 235, 49–57. [Google Scholar] [CrossRef] [PubMed]
- McInnes, E. Pathology for Toxicologists: Principles and Practices of Laboratory Animal Pathology for Study Personnel; Wiley-Blackwell: Hoboken, NJ, USA, 2017. [Google Scholar]
- Perez-Alenza, M.D.; Blanco, J.; Sardon, D.; Sanchez Moreiro, M.A.; Rodriguez-Bertos, A. Clinico-pathological findings in cattle exposed to chronic bracken fern toxicity. N. Z. Vet. J. 2006, 54, 185–192. [Google Scholar] [CrossRef] [PubMed]
- Bekkevold, C.M.; Robertson, K.L.; Reinhard, M.K.; Battles, A.H.; Rowland, N.E. Dehydration parameters and standards for laboratory mice. J. Am. Assoc. Lab. Anim. Sci. 2013, 52, 233–239. [Google Scholar] [PubMed]
- Billett, H.H. Hemoglobin and hematocrit. In Clinical Methods: The History, Physical, and Laboratory Examinations; Walker, H.K., Hall, W.D., Hurst, J.W., Eds.; Butterworths: Boston, MA, USA, 1990. [Google Scholar]
- Brown, T.J.; Hammers, M.; Taylor, M.; Dugdale, H.L.; Komdeur, J.; Richardson, D.S. Hematocrit, age, and survival in a wild vertebrate population. Ecol. Evol. 2021, 11, 214–226. [Google Scholar] [CrossRef] [PubMed]
- Unegbu, C.C.; Ajah, O.; Onwusonye, J.C.; Anyanwu, O.O.; Duru, C.A. Antidiabetic properties of combined methanol extracts of Pteridium aquilinum, Mucuna pruriens and Newbouldia laevis in alloxan induced diabetes in rats. World J. Pharm. Res. 2021, 10, 97–111. [Google Scholar] [CrossRef]
- Gomes, J.; Magalhães, A.; Michel, V.; Amado, I.F.; Aranha, P.; Ovesen, R.G.; Hansen, H.C.B.; Gärtner, F.; Reis, C.A.; Touati, E. Pteridium aquilinum and its ptaquiloside toxin induce DNA damage response in gastric epithelial cells: A link with gastric carcinogenesis. Toxicol. Sci. 2012, 126, 60–71. [Google Scholar] [CrossRef] [PubMed]
- Latorre, A.; Akinaga, R.; Haraguchi, M.; Górniak, S. Spleen damage in response to Pteridium aquilinum administration in mice. Toxicol. Pathol. 2008, 36, 167–168. [Google Scholar] [CrossRef]
- Costa, A.C.; Santos, J.M.O.; Gil da Costa, R.M.; Medeiros, R. Impact of immune cells on the hallmarks of cancer: A literature review. Crit. Rev. Oncol. Hematol. 2021, 168, 103541. [Google Scholar] [CrossRef] [PubMed]
- Dion, C.; Haug, C.; Guan, H.; Ripoll, C.; Spiteller, P.; Coussaert, A.; Boulet, E.; Schmidt, D.; Wei, J.; Zhou, Y. Evaluation of the anti-inflammatory and antioxidative potential of four fern species from China intended for use as food supplements. Nat. Prod. Commun. 2015, 10, 1934578X1501000416. [Google Scholar] [CrossRef]
- Xu, W.; Zhang, F.; Luo, Y.; Ma, L.; Kou, X.; Huang, K. Antioxidant activity of a water-soluble polysaccharide purified from Pteridium aquilinum. Carbohydr. Res. 2009, 344, 217–222. [Google Scholar] [CrossRef] [PubMed]
- Williams, V.M.; Filippova, M.; Filippov, V.; Payne, K.J.; Duerksen-Hughes, P. Human papillomavirus type 16 E6* induces oxidative stress and DNA damage. J. Virol. 2014, 88, 6751–6761. [Google Scholar] [CrossRef] [PubMed]







| Peak | RT (min) | UV | [M-H]− (m/z) | MS/MS Fragments | Tentative Assignment |
|---|---|---|---|---|---|
| 1 | 1.4 | 265, 374 | 133 | MS2[133] = 115, 71, 87 | Malic acid |
| 2 | 1.8 | 264 | 191 | MS2[191] = 111, 173, 129 | Citric acid |
| 3 | 7.6 | 289 | 341 | MS2[341] = 179, 135 | Caffeic acid glucoside |
| 4 | 12.0 | 218, 261, 299 | 441 | MS2[441] = 179, 395, 161, 143, 131 | Pteroside C, P or M |
| 5 | 12.6 | 227, 290 | 433 | MS2[433] = 313, 343, 415 | Naringenin-C-hexoside |
| 6 | 13.2 | 232sh, 253, 290, 300sh, 331sh | 513 | MS2[513] = 469, 295, 269, 313, 339 MS3[513 → 469] = 295, 269, 313, 159, 199 | Brainic acid |
| 7 | 13.6 | 220, 263, 306 | 455 | MS2[455] = 379, 409, 179, 161, 143 | Pteroside A or A2 |
| 8 | 13.7 | 235, 291, 327 | 519 | MS2[519] = 475, 409, 179 MS3[519 → 475] = 313 | Blechnic acid hexose |
| 9 | 13.9 | 219, 264, 303 | 455 | MS2[455] = 409, 391, 161 | Pteroside D |
| 10 | 16.1 | 217, 261, 304 | 425 | MS2[425] = 179, 379, 161, 143 | Pteroside X or W |
| 11 | 17.3 | 219, 261, 304 | 465 | MS2[465] = 285, 391, 405, 423, 259, 243, 447, 373, 329 | Pteroside derivative |
| Peak | RT (min) | λmax (nm) | [M-H]− (m/z) | ESI-MS Fragments (m/z) | Probable Compound |
|---|---|---|---|---|---|
| 1 | 1.3 | 276 | 133 | MS2[133] = 115, 71, 87 | Malic acid |
| 2 | 1.6 | 280, 235sh | 191 | MS2[191] = 111, 173, 129 | Citric acid |
| 3 | 9.9 | 325, 301sh | 335 | MS2[335] = 179, 135, 161, 291 | Caffeoyl-shikimic acid |
| 4 | 10.1 | 326, 300sh | 335 | MS2[335] = 179, 135, 161, 291 | Caffeoyl-shikimic acid (isomer) |
| 5 | 11.1 | 250, 289sh 303, 335sh | 403 * | MS2[403] = 385, 241, 375, 269, 343, 323, 359 | Blechnic acid |
| 6 | 12.1 | 250, 290sh, 302, 336sh | 403 * | MS2[403] = 359, 385, 269, 313, 291, 341, 193 | Blechnic acid (isomer) |
| 7 | 12.9 | 265, 345 | 447 | MS2[447]: 285, 327, 255, 151 MS3[447 → 285]: 257, 267, 241, 229, 213, 197, 163 | Kaempferol-hexoside |
| 8 | 16.6 | 265, 345 | 533 | MS2[533] = 489, 445, 515, 371 | Kaempferol-malonylhexoside |
| 9 | 15.7 | 225, 241 290, 321 | 365 | MS2[365]: 229, 135, 161, 185 MS3[365 → 229]: 185, 100, 130 | Caffeoyl-tryptofan |
| 10 | 15.9 | 243, 291, 318 | 593 | MS2[593]: 285, 447, 307, 257 MS3[593 → 285]: 257, 151, 241, 213, 267, 229 | Kaempferol-rutinoside |
| 11 | 16.8 | 266 | 465 | MS2[465] = 235, 220, 327, 271, 447 | Unknown |
| 12 | 17.0 | 290, 310sh, 240sh | 349 | MS2[349] = 229, 186, 145, 305, 220 | Coumaroyl-tryptophan |
| 13 | 17.3 | 242, 290, 319 | 379 | MS2[379] = 229, 175, 335, 186 | Feruloyl-tryptophan |
| Groups | Humane Endpoints | Body Weight | Weight Gain (%) | Average Daily Consumption | ||
|---|---|---|---|---|---|---|
| Initial (g) | Final (g) | Food (g) | Drink (mL) | |||
| Assay 1: extract of Pteridium aquilinum rhizomes | ||||||
| G1 (WT, control) | 0.00 ± 0.00 | 29.72 ± 2.10 | 29.39 ± 2.47 | −1.16 ± 3.00 | 3.52 | 4.61 |
| G2 (WT, 0.05 g/mL) | 0.00 ± 0.00 | 29.41 ± 2.66 | 30.94 ± 3.16 | 5.16 ± 4.36 1 | 3.65 | 6.84 |
| G3 (HPV, control) | 0.04 ± 0.69 | 28.31 ± 2.63 | 28.15 ± 3.04 | −0.62 ± 3.75 | 4.35 | 7.40 |
| G4 (HPV, 0.0125 g/mL) | 0.04 ± 0.89 | 26.99 ± 2.37 | 26.52 ± 2.06 | −1.66 ± 2.43 | 4.21 | 8.39 |
| G5 (HPV, 0.025 g/mL) | 0.12 ± 0.11 | 26.17 ± 3.77 | 25.39 ± 3.84 | −2.92 ± 6.21 | 4.19 | 7.56 |
| G6 (HPV, 0.05 g/mL) | 0.10 ± 0.14 | 28.59 ± 3.57 | 27.30 ± 2.84 | −4.28 ± 2.61 | 4.58 | 10.00 |
| Assay 2: extract of freeze-dried fiddleheads of Pteridium aquilinum | ||||||
| G1 (WT, control) | 0.00 ± 0.00 | 26.04 ± 0.46 | 30.42 ± 3.02 | 16.73 ± 10.02 | 3.73 | 4.15 |
| G2 (WT, 50% PTE) | 0.00 ± 0.00 | 24.85 ± 2.37 | 27.37 ± 3.03 | 10.43 ± 10.91 | 4.80 | 4.58 |
| G3 (HPV, control) | 0.25 ± 0.16 | 25.09 ± 0.71 | 26.86 ± 1.19 | 7.05 ± 2.45 | 4.43 | 7.42 |
| G4 (HPV, 12.5% PTE) | 0.12 ± 0.12 | 26.40 ± 1.93 | 28.00 ± 1.96 | 6.13 ± 3.47 | 4.25 | 6.92 |
| G5 (HPV, 25% PTE) | 0.16 ± 0.22 | 26.14 ± 1.41 | 26.93 ± 1.56 | 3.06 ± 4.08 | 4.43 | 7.08 |
| G6 (HPV, 50% PTE) | 0.12 ± 0.12 | 25.55 ± 1.25 | 26.86 ± 0.95 | 5.23 ± 4.42 | 4.69 | 7.09 |
| Groups | Heart | Lung | Spleen | Liver | Kidneys |
|---|---|---|---|---|---|
| Assay 1: extract of Pteridium aquilinum rhizomes | |||||
| G1 (WT, control) | 5.00 ± 1.62 | 6.20 ± 1.10 | 4.44 ± 0.38 | 41.46 ± 3.93 | 6.06 ± 1.03 |
| G2 (WT, 0.05 g/mL) | 4.50 ± 0.72 | 6.18 ± 0.67 | 3.84 ± 0.46 | 41.04 ± 2.90 1 | 5.90 ± 0.45 |
| G3 (HPV, control) | 4.66 ± 0.55 | 6.64 ± 1.26 | 6.72 ± 2.62 | 45.26 ± 5.42 1 | 7.28 ± 1.11 |
| G4 (HPV, 0.0125 g/mL) | 4.86 ± 0.77 | 7.20 ± 0.70 | 5.94 ± 2.49 | 48.16 ± 5.71 | 6.62 ± 0.49 |
| G5 (HPV, 0.025 g/mL) | 4.48 ± 0.32 | 7.90 ± 2.02 | 7.70 ± 3.14 | 50.06 ± 3.06 | 6.96 ± 1.54 |
| G6 (HPV, 0.05 g/mL) | 5.40 ± 0.99 | 7.54 ± 0.83 | 7.28 ± 2.91 | 54.00 ± 3.48 | 7.28 ± 0.78 |
| Assay 2: extract of freeze-dried fiddleheads of Pteridium aquilinum | |||||
| G1 (WT, control) | 4.16 ± 0.34 | 7.25 ± 0.84 | 4.14 ± 0.82 | 43.87 ± 3.90 2 | 5.13 ± 0.53 2 |
| G2 (WT, 50% PTE) | 4.12 ± 0.57 | 6.67 ± 0.27 | 3.73 ± 0.32 | 43.25 ± 2.66 | 4.97 ± 0.28 1 |
| G3 (HPV, control) | 4.47 ± 0.46 | 6.92 ± 0.57 | 7.09 ± 4.55 | 50.88 ± 3.70 | 6.22 ± 0.28 |
| G4 (HPV, 12.5% PTE) | 4.44 ± 0.42 | 6.23 ± 0.39 | 5.37 ± 0.52 | 48.19 ± 1.64 | 5.67 ± 0.54 |
| G5 (HPV, 25% PTE) | 4.55 ± 0.42 | 6.45 ± 0.32 | 5.30 ± 1.00 | 48.42 ± 4.27 | 5.57 ± 0.18 |
| G6 (HPV, 50% PTE) | 4.62 ± 0.59 | 7.07 ± 0.76 | 5.37 ± 0.46 | 46.03 ± 2.20 | 6.04 ± 0.42 |
| Parameters/Groups | G1 WT Control | G2 WT 0.05 g/mL | G3 HPV control | G4 HPV 0.0125 g/mL | G5 HPV 0.025 g/mL | G6 HPV 0.05 g/mL |
|---|---|---|---|---|---|---|
| Hematocrit (%) | 46.55 ± 1.64 | 48.78 ± 2.90 | 37.93 ± 15.33 | 47.88 ± 3.16 | 45.76 ± 2.92 | 42.06 ± 15.29 |
| Hemoglobin (M/μL) | 15.15 ± 0.44 | 15.76 ± 0.77 | 12.33 ± 4.69 | 15.30 ± 1.10 | 14.46 ± 1.21 | 13.44 ± 4.82 |
| Neutrophils (K/d/μL) | 0.980 ± 0.37 | 0.966 ± 0.40 | 1.97 ± 0.95 | 0.828 ± 0.33 | 1.30 ± 0.95 | 5.36 ± 9.39 |
| Lymphocytes (K/μL) | 2.03 ± 0.96 | 1.85 ± 1.08 | 0.805 ± 0.09 | 1.17 ± 0.72 | 1.12 ± 0.54 | 2.25 ± 1.17 |
| Monocytes (K/μL) | 0.043 ± 0.03 | 0.076 ± 0.06 | 0.058 ± 0.06 | 0.050 ± 0.02 | 0.112 ± 0.14 | 0.436 ± 0.82 |
| Eosinophils (K/μL) | 0.04 ± 0.04 | 0.06 ± 0.02 | 0.07 ± 0.09 | 0.03 ± 0.03 | 0.08 ± 0.06 | 0.14 ± 0.07 |
| Basophils (K/μL) | 0.03 ± 0.01 | 0.02 ± 0.01 | 0.02 ± 0.01 | 0.04 ± 0.02 | 0.03 ± 0.04 | 0.03 ± 0.04 |
| Leukocytes (K/μL) | 3.12 ± 1.18 | 2.97 ± 1.41 | 2.92 ± 1.13 | 2.12 ± 1.10 | 2.64 ± 1.28 | 8.31 ± 11.36 |
| Platelets (K/μL) | 649.00 ± 127.28 | 782.40 ± 131.51 | 841.30 ± 462.14 | 1187.00 ± 180.60 | 1085.20 ± 133.12 | 981.20 ± 241.25 |
| Erythrocytes (M/μL) | 9.99 ± 0.27 | 10.7 ± 0.56 | 8.01 ± 3.00 | 10.18 ± 0.50 | 9.63 ± 0.88 | 8.92 ± 3.26 |
| Reticulocytes (K/μL) | 507.40 ± 74.98 | 509.00 ± 93.71 | 480.70 ± 92.10 | 482.70 ± 81.62 | 561.4 ± 98.03 | 386.10 ± 102.20 |
| MPV | 8.13 ± 0.53 | 8.06 ± 0.46 | 8.25 ± 0.78 | 7.90 ± 0.24 | 8.10 ± 0.33 | 8.02 ± 0.23 |
| PDW | 7.03 ± 0.73 | 6.96 ± 0.33 | 6.60 ± 0.14 | 6.83 ± 0.22 | 6.48 ± 0.24 | 6.64 ±0.49 |
| MCV | 46.60 ± 1.11 | 45.68 ±1.23 | 46.58 ± 3.41 | 47.00 ± 1.02 | 47.62 ± 1.71 | 47.20 ± 0.78 |
| MCH | 15.18 ± 0.13 | 14.76 ± 0.25 | 15.25 ± 0.56 | 15.00 ± 0.45 | 15.04 ± 0.39 | 15.16 ± 0.25 |
| MCHC | 32.55 ± 0.61 | 32.32 ± 0.45 | 32.80 ± 1.69 | 31.95 ± 0.26 | 31.58 ± 0.56 | 32.10 ± 0.80 |
| Glucose | 215.60 ± 39.53 | 231.30 ± 55.81 | 204.40 ± 61.52 | 152.40 ± 45.51 | 157.60 ± 50.34 | 162.60 ± 30.24 |
| Total proteins (g/dL) | 5.00 ± 0.24 | 5.48 ± 0.30 | 5.30 ± 1.09 | 5.90 ± 0.42 | 5.78 ± 0.81 | 5.34 ± 0.38 |
| Albumine (g/dL) | 2.49 ± 1.03 | 2.82 ± 0.18 | 2.37 ± 1.07 | 3.11 ± 0.04 | 3.10 ± 0.31 | 2.84 ± 0.24 |
| ALAT (U/L) | 22.86 ± 10.89 | 28.72 ± 4.97 | 51.15 ± 31.32 | 33.60 ± 14.60 | 31.05 ± 4.74 | 34.80 ± 17.87 |
| Parameters/Groups | G1 WT Control | G2 WT 50% PTE | G3 HPV Control | G4 HPV 12.5% PTE | G5 HPV 25% PTE | G6 HPV 50% PTE |
|---|---|---|---|---|---|---|
| Hematocrit (%) | 48.10 ± 2.24 | 47.96 ± 1.61 | 46.30 ± 1.39 | 46.18 ± 2.62 | 45.16 ± 2.03 | 47.28 ± 1.40 |
| Hemoglobin (M/μL) | 15.06 ± 0.55 | 15.28 ± 0.61 | 14.44 ± 0.50 | 14.74 ± 0.67 | 14.56 ± 0.55 | 15.00 ± 0.42 |
| Neutrophils (K/d/μL) | 0.76 ± 0.58 | 1.01 ± 0.45 | 0.89 ± 0.38 | 1.16 ± 0.32 | 1.18 ± 0.37 | 1.64 ± 0.39 |
| Lymphocytes (K/μL) | 2.26 ± 0.41 | 2.29 ± 0.60 | 2.28 ± 0.68 | 1.84 ± 0.73 | 1.83 ± 0.36 | 2.90 ± 1.03 |
| Monocytes (K/μL) | 0.05 ± 0.03 | 0.07 ± 0.01 | 0.26 ± 0.36 | 0.10 ± 0.04 | 0.10 ± 0.06 | 0.11 ± 0.04 |
| Eosinophils (K/μL) | 0.07 ± 0.02 | 0.05 ± 0.01 | 0.12 ± 0.08 | 0.07 ± 0.02 | 0.10 ± 0.06 | 0.10 ± 0.05 |
| Basophils (K/μL) | 0.01 ± 0.01 | 0.01 ± 0.02 | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.02 ± 0.01 | 0.01 ± 0.01 |
| Leukocytes (K/μL) | 3.15 ± 0.88 | 3.43 ± 0.95 | 3.56 ± 1.21 | 3.19 ± 0.85 | 3.23 ± 0.50 | 4.76 ± 1.36 |
| Platelets (K/μL) | 637.80 ± 279.58 | 535.20 ± 167.96 | 875.40 ± 389.96 | 947.60 ± 399.20 | 983.20 ± 163.18 | 823.80 ± 139.64 |
| Erythrocytes (M/μL) | 9.71 ± 0.58 | 9.60 ± 0.17 | 9.77 ± 0.13 | 9.64 ± 0.43 | 9.57 ± 0.33 | 9.62 ± 0.37 |
| Reticulocytes (K/μL) | 531.34 ± 159.65 | 418.80 ± 123.26 | 487.08 ± 124.11 | 402.94 ± 126.37 | 353.02 ± 88.48 | 385.74 ± 58.30 |
| MPV | 8.48 ± 0.18 | 8.32 ± 0.16 | 8.30 ± 0.22 | 8.40 ± 0.72 | 8.20 ± 0.16 | 8.42 ± 0.24 |
| PDW | 7.68 ± 0.27 | 7.38 ± 0.54 | 7.62 ± 0.41 | 7.50 ± 0.34 | 7.24 ± 0.21 | 7.86 ± 0.46 |
| MCV | 49.54 ± 1.10 | 49.88 ± 1.29 | 47.40 ± 1.57 | 47.88 ± 0.78 | 47.18 ± 0.94 | 49.20 ± 1.29 |
| MCH | 15.50 ± 0.47 | 15.90 ± 0.49 | 14.80 ± 0.58 | 15.30 ± 0.16 | 15.24 ± 0.17 | 15.60 ± 0.29 |
| MCHC | 31.32 ± 0.61 | 31.86 ± 0.26 | 31.18 ± 0.78 | 31.94 ± 0.64 | 32.24 ± 0.39 | 31.72 ± 0.33 |
| Glucose | 159.60 ± 32.49 | 144.60 ± 21.42 | 179.60 ± 38.23 | 150.00 ± 41.44 | 135.60 ± 30.42 | 156.60 ± 41.75 |
| Total proteins (g/dL) | 5.44 ± 0.36 | 5.52 ± 0.23 | 6.00 ± 0.80 | 5.92 ± 0.18 | 5.56 ± 0.26 | 5.72 ± 0.23 |
| Albumine (g/dL) | 3.52 ± 0.19 | 3.34 ± 0.33 | 3.18 ± 0.19 | 3.15 ± 0.22 | 3.25 ± 0.20 | 3.10 ± 0.19 |
| ALAT (U/L) | 35.28 ± 7.64 | 40.42 ± 24.08 | 54.30 ± 10.49 | 47.08 ± 9.30 | 50.04 ± 12.09 | 49.70 ± 21.65 |
| Histological Lesions | G1 WT Control | G2 WT 0.05 g/mL | G3 HPV Control | G4 HPV 0.0125 g/mL | G5 HPV 0.025 g/mL | G6 HPV 0.05 g/mL |
|---|---|---|---|---|---|---|
| EAR PAVILION LESIONS | ||||||
| HYPERPLASIA | ||||||
| 0(0%) 1 | 0(0%) 2 | 3(60%) | 4(80%) | 5(100%) | 4(80%) | |
| DYSPLASIA | ||||||
| 0(0%) 1 | 0(0%) 2 | 4(80%) | 3(60%) | 2(40%) | 4(80%) | |
| CARCINOMA | ||||||
| Carcinoma in situ | 0(0%) | 0(0%) | 1(20%) | 0(0%) | 0(0%) | 1(20%) |
| Squamous cell carcinoma | 0(0%) | 0(0%) | 1(20%) | 0(0%) | 2(40%) | 0(0%) |
| Invasive carcinoma | 0(0%) | 0(0%) | 0(0%) | 1(20%) | 0(0%) | 1(20%) |
| OTHER LESIONS | ||||||
| Papilloma | 0(0%) | 0(0%) | 0(%) | 2(40%) | 2(40%) | 0(0%) |
| Hyperkeratosis—Orthokeratosis | 0(0%) | 0(0%) 2 | 2(40%) | 3(60%) | 3(60%) | 4(80%) |
| Hyperkeratosis—Parakeratosis | 0(0%) 1 | 0(0%) 2 | 5(100%) 3 | 4(80%) | 1(20%) | 4(80%) |
| Ulcer | 0(0%) | 0(0%) | 2(40%) | 0(0%) | 0(0%) | 1(20%) |
| CHEST SKIN LESIONS | ||||||
| HYPERPLASIA | ||||||
| 0(0%) | 0(0%) 2 | 2(40%) | 3(60%) | 2(40%) | 5(100%) | |
| DYSPLASIA | ||||||
| 0(0%) | 0(0%) 2 | 1(20%) | 3(60%) | 0(0%) | 4(80%) | |
| CARCINOMA | ||||||
| Carcinoma in situ | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) |
| Squamous cell carcinoma | 0(0%) | 0(0%) | 1(20%) | 0(0%) | 2(40%) | 1(20%) |
| Invasive carcinoma | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) |
| OTHER LESIONS | ||||||
| Papilloma | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) |
| Hyperkeratosis—Orthokeratosis | 0(0%) | 0(0%) 2 | 0(%) 2 | 2(40%) | 2(40%) 2 | 5(100%) |
| Hyperkeratosis—Parakeratosis | 0(0%) | 0(0%) 2 | 1(20%) 2 | 1(20%) 2 | 1(20%) 2 | 5(100%) |
| Ulcer | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 2(40%) | 0(0%) |
| LIVER | ||||||
| Extramedullary hematopoiesis | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 1(20%) | 1(20%) |
| Mononuclear infiltrate | 0(0%) | 4(80%) 2 | 1(20%) | 1(20%) | 0(0%) | 0(0%) |
| Subacute multifocal hepatitis | 0(0%) | 0(0%) | 2(40%) | 1(20%) | 0(0%) | 1(20%) |
| Necrosis | 0(0%) | 0(0%) | 1(20%) | 0(0%) | 0(0%) | 1(20%) |
| SPLEEN | ||||||
| Lymphoid hyperplasia | 0(0%) | 1(20%) | 2(40%) | 2(40%) | 0(0%) | 0(0%) |
| Hemosiderosis | 0(0%) | 2(40%) | 0(0%) | 0(0%) | 1(20%) | 2(40%) |
| Histological Lesions | G1 WT Control | G2 WT 50% PTE | G3 HPV Control | G4 HPV 12.5% PTE | G5 HPV 25% PTE | G6 HPV 50% PTE |
|---|---|---|---|---|---|---|
| EAR PAVILION LESIONS | ||||||
| HYPERPLASIA | ||||||
| 0(0%) | 1(20%) | 3(60%) | 3(60%) | 4(80%) | 2(20%) | |
| DYSPLASIA | ||||||
| 0(0%) | 0(0%) | 4(80%) | 2(40%) | 3(60%) | 4(80%) | |
| CARCINOMA | ||||||
| 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | |
| OTHER LESIONS | ||||||
| Sebaceous hyperplasia | 0(0%) | 0(0%) 1 | 0(0%) 1 | 0(0%) 1 | 2(40%) | 5(100%) |
| Papilloma | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) |
| Hyperkeratosis—Parakeratotic | 0(0%) | 0(0%) 1 | 4(80%) | 5(100%) | 4(80%) | 5(100%) |
| Inflammatory infiltrate | 0(0%) 2 | 0(0%) 1 | 5(100%) | 5(100%) | 5(100%) | 5(100%) |
| Erosion | 0(0%) | 0(0%) | 0(0%) | 3(60%) | 0(0%) | 0(0%) |
| Ulceration | 0(0%) | 0(0%) | 1(20%) | 0(0%) | 0(0%) | 1(20%) |
| Severe deformation | 0(0%) | 0(0%) 1 | 0(0%) 1 | 0(0%) 1 | 4(80%) | 5(100%) |
| CHEST SKIN LESIONS | ||||||
| Sebaceous hyperplasia | 0(0%) | 0(0%) 1 | 3(60%) | 3(60%) | 4(80%) | 5(100%) |
| HYPERPLASIA | ||||||
| 0(0%) | 0(0%) | 2(40%) | 2(40%) | 1(20%) | 0(0%) | |
| DYSPLASIA | ||||||
| 0(0%) | 0(0%) | 1(20%) | 1(20%) | 0(0%) | 0(0%) | |
| CARCINOMA | ||||||
| 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | |
| OTHER LESIONS | ||||||
| Inflammatory infiltrate | 0(0%) | 1(20%) | 4(80%) | 3(60%) | 1(20%) | 4(80%) |
| Cyst dermoid | 0(0%) | 0(0%) | 0(0%) | 1(20%) | 0(0%) | 0(0%) |
| LIVER | ||||||
| Inflammatory Infiltrate | 0(0%) | 4(80%) | 2(40%) | 0(0%) | 4(80%) | 4(80%) |
| Tumefaction | 0(0%) | 0(0%) | 0(0%) | 1(20%) | 2(40%) | 1(20%) |
| Hydropic degeneration | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) |
| SPLEEN | ||||||
| Hyperemia | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) |
| Inflammatory infiltrate | 0(0%) | 0(0%) | 2(40%) | 5(100%) | 4(80%) | 2(40%) |
| Mesangial expansion | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) |
| Hydronephrosis | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Medeiros-Fonseca, B.; Faustino-Rocha, A.I.; Pires, M.J.; Neuparth, M.J.; Queiroga, F.; Gaivão, I.; Catarino, M.D.; Cardoso, S.M.; Bastos, M.M.; Félix, L.; et al. Toxicological Activities of Pteridium aquilinum Rhizomes and Fiddleheads in HPV16-Transgenic Mice. Biology 2026, 15, 976. https://doi.org/10.3390/biology15120976
Medeiros-Fonseca B, Faustino-Rocha AI, Pires MJ, Neuparth MJ, Queiroga F, Gaivão I, Catarino MD, Cardoso SM, Bastos MM, Félix L, et al. Toxicological Activities of Pteridium aquilinum Rhizomes and Fiddleheads in HPV16-Transgenic Mice. Biology. 2026; 15(12):976. https://doi.org/10.3390/biology15120976
Chicago/Turabian StyleMedeiros-Fonseca, Beatriz, Ana I. Faustino-Rocha, Maria João Pires, Maria João Neuparth, Felisbina Queiroga, Isabel Gaivão, Marcelo D. Catarino, Susana M. Cardoso, Margarida M. Bastos, Luís Félix, and et al. 2026. "Toxicological Activities of Pteridium aquilinum Rhizomes and Fiddleheads in HPV16-Transgenic Mice" Biology 15, no. 12: 976. https://doi.org/10.3390/biology15120976
APA StyleMedeiros-Fonseca, B., Faustino-Rocha, A. I., Pires, M. J., Neuparth, M. J., Queiroga, F., Gaivão, I., Catarino, M. D., Cardoso, S. M., Bastos, M. M., Félix, L., Venâncio, C., Seixas, F., Vasconcelos-Nóbrega, C., Vala, H., Medeiros, R., Oliveira, P. A., & Gil da Costa, R. M. (2026). Toxicological Activities of Pteridium aquilinum Rhizomes and Fiddleheads in HPV16-Transgenic Mice. Biology, 15(12), 976. https://doi.org/10.3390/biology15120976

